Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Similar documents
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Viral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel. Basel,

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Case n 1 ( B 92 / 4208 ) Case n 2 ( B 00 / 8249 ) Case n 3 ( B 98 / 8352 )

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

BSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D

Steatotic liver disease

2014 CURRENT ISSUES IN PATHOLOGY

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Liver Transplant Pathology a general view

Effect of the number of portal area on modified histological activity index of viral hepatitis and histological findings

Relationship between Serum Iron Indices and Hepatic Iron Quantitation in Patients with Fatty Liver Disease

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

-sheet 3. -Waseem Alhaj. Maha Shomaf

Original Article. Significance of Hepatic Steatosis in Chronic Hepatitis B Infection INTRODUCTION

Liver Pathology in the 0bese

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis

Chronic viral hepatitis: The histology report

HIV/AIDS and the Liver : interlinking challenges

Nottingham Patterns of liver fibrosis and their clinical significance

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015

British Liver Transplant Group Pathology meeting September Leeds cases

Special stains in liver pathology

National Liver EQA Scheme. Open meeting, Glasgow March 24th 2004

Fibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes. Carla Venturi Monteagudo MD, PhD

A Systematic Approach to Medical Liver Disease

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Non-Alcoholic Fatty Liver Disease An Update

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

The Long Term Care Risk

Pretreatment Evaluation

Hereditary Haemochromatosis (A pint too many: discussing haemochromatosis) John Lee

NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN

Acute and Chronic Hepatitis John Hart, M.D. University of Chicago Medical Center

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1

ACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

Use of Ultrasound in NAFLD

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Steatosi epatica ed HCV

Transient elastography in chronic liver diseases of other etiologies

Cryptogenic Cirrhosis: An Approach To The Diagnosis In The Era Of Molecular and Genomic Medicine

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

Understanding Root Cause: Pathogenesis of Hepatic Fibrosis

9/28/2016. Elevated Liver Function Tests: A Case Based Approach. Objectives. Identify patterns of abnormal liver function tests

Conflicts of interest disclosures

Screening cardiac patients for advanced liver disease

LIVER PATHOLOGY. Thursday 28 th November 2013

Hepatology for the Nonhepatologist

Autoimmune Liver Diseases

Hemosiderin. Livia Vida 2018

All You Wanted to Know About Hepatocellular Carcinoma

Liver National EQA Scheme. Circulation Q Birmingham, March 15 th 2005

PROGRAMME AT A GLANCE

Autoimmune Hepatitis in Clinical Practice

Nash with cirrhosis icd 10

Natural History of Chronic Hepatitis B

Module 1 Introduction of hepatitis

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Pegylated Interferons and Ribavirins

EVALUATION OF ABNORMAL LIVER TESTS

Understanding your FibroScan Results

Clinical dilemmas in HBeAg-negative CHB

Abnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital

Approach to the Patient with Liver Disease

AASLD: Boston Rob Goldin

Malignant Focal Liver Lesions

Pathology of Fatty Liver Disease

Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation

Clinical cases: HIV/HCV coinfection

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Management of Patients with Chronic Hepatitis B: The Alaska Experience

Il trapianto di cellule staminali emopoietiche nel paziente portatore di virus epatitici

Hepatitis B screening and surveillance in primary care

Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF

Steatosis/Steatohepatitis

11 th Banff Conference on Allograft Pathology - An Update

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of

Hepatology for Gastroenterologists and Hematologists. Part Three: Pathology of Chronic Necroinflammatory Liver Disease

NAFLD & NASH: Russian perspective

HBV in HIV Forgotten but not Gone

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham

Diffuse Liver Disease:

Natural History of HBV Infection

Transmission of HCV in the United States (CDC estimate)

Pathology of The Liver - Practice. 2017/ semester

AMR in Liver Transplantation: Incidence

Hepatitis C Management and Treatment

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Evaluation of Liver Mass Lesions. American College of Gastroenterology 2013 Regional Postgraduate Course

Autoimmune Hepatitis Events Easl

Interesting Cases from Liver Tumor Board. Jeffrey C. Weinreb, M.D.,FACR Yale University School of Medicine

Transcription:

Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging for further reference: Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach Neil Theise, MD. Depts of Pathology and Medicine (Digestive Diseases) Beth Israel Medical Center Albert Einstein College of Medicine New York City www.neiltheise.com Confirm clinical diagnosis Confirm clinical diagnosis Stage fibrosis Grade necroinflammation Role of Liver Biopsy Role of Liver Biopsy 1

Severe activity: Confluent necrosis Severe activity: Confluent necrosis Severe activity: Confluent necrosis Confluent necrosis, think about: In HBV: - HBeAg to Ab conversion - HDV super-infection on HBV In HCV: - HCV acute exacerbation - Immunocompromise (undx d HIV) - Concomitant autoimmune hepatitis Always: - Drug/toxin mediated injury 2

Stages of Fibrosis Batts-Ludwig (or a modified Ishak) Ishak Metavir 1 2 3 4 1 2 focal frequent 3 4 focal frequent 5 6 1 2 3 4 focal frequent Confirm clinical diagnosis Stage fibrosis Role of Liver Biopsy Grade necroinflammation Evaluate possible concomitant diseases Portal Fibosis Fibrous Septa Transition to Cirrhosis Cirrhosis Theise ND. Human Pathology 2007 Other diseases Other diseases 3

HCV associated steatosis vs. concomitant fatty liver disease HCV Associated Steatosis Concomitant Fatty Liver Disease (ALD or NAFLD) Severity Mild Mild, Moderate or Severe HCV Associated Steatosis Concomitant Fatty Liver Disease (ALD or NAFLD) HCV Associated Steatosis Concomitant Fatty Liver Disease (ALD or NAFLD) Severity Mild Mild, Moderate or Severe Distribution Random Zonal (zone 3, progressing to 1) Severity Mild Mild, Moderate or Severe Distribution Random Zonal (zone 3, progressing to 1) Steatohepatitis 4

HCV Associated Steatosis Concomitant Fatty Liver Disease (ALD or NAFLD) HCV Associated Steatosis Concomitant Fatty Liver Disease (ALD or NAFLD) Severity Mild Mild, Moderate or Severe Distribution Random Zonal (zone 3, progressing to 1) Steatohepatitis Absent Variable Severity Mild Mild, Moderate or Severe Distribution Random Zonal (zone 3, progressing to 1) Steatohepatitis Absent Variable Steatofibrosis HCV Associated Steatosis Concomitant Fatty Liver Disease (ALD or NAFLD) HCV Associated Steatosis Concomitant Fatty Liver Disease (ALD or NAFLD) Severity Mild Mild, Moderate or Severe Distribution Random Zonal (zone 3, progressing to 1) Steatohepatitis Absent Variable Steatofibrosis Absent Variable Severity Mild Mild, Moderate or Severe Distribution Random Zonal (zone 3, progressing to 1) Steatohepatitis Absent Variable Steatofibrosis Absent Variable Lipogranulomas +/- +/- 5

Case 1 44 year old man with HCV and mild ALT/AST elevations 6

Case 1: Diagnoses Fibrous septum formation with mixed features of: - chronic hepatitis C (mildly active) - fatty liver disease (? alcoholic vs. non-alcoholic) Case 1: Diagnoses Fibrous septum formation with mixed features of: - chronic hepatitis C (mildly active) - fatty liver disease (? alcoholic vs. non-alcoholic) Comment: The amount of steatosis in the specimen is significantly more than is usually seen with hepatitis C alone, implying possible concomitant fatty liver disease Other diseases BUT!!! Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Vanni et al. Hepatology Sep 2009; 50: 697. Case 1: Diagnoses Fibrous septum formation with mixed features of: - chronic hepatitis C (mildly active) - fatty liver disease (? alcoholic vs. non-alcoholic) Comment: The amount of steatosis in the specimen is significantly more than is usually seen with hepatitis C alone, implying possible concomitant fatty liver disease; however, it must be kept in mind that hepatitis C itself may lead to insulin resistance in some patients and thus may also be a direct cause of non-alcoholic fatty liver disease. 7

Other diseases HCV associated iron vs. other 2 ndary causes vs. Hereditary Hemochromatosis (type 1: HFE mutated) Severity HCV Associated Iron Type I Hereditary Hemochromatosis Grading of iron Grade 1 zone 1, some periportal areas Grade 2 zone 1, all periportal areas Grade 3 zones 1 and 2 Grade 4 zones 1, 2, and 3 8

HCV Associated Iron Type I Hereditary Hemochromatosis Severity Grade 1/4 to 2/4 Grade 1/4 to 4/4 Case 2 56 year old man referred for HCV and mild liver test elevation 9

10

Case 2: Diagnoses - Chronic hepatitis, mildly active with transition to cirrhosis (modified Ishak stage 3/4), compatible with hepatitis C. - Hemosiderosis, grade 1/4,? Hereditary vs. secondary hemochromatosis Case 2: Diagnoses - Chronic hepatitis, mildly active with transition to cirrhosis (modified Ishak stage 3/4), compatible with hepatitis C. - Hemosiderosis, grade 1/4,? Hereditary vs. secondary hemochromatosis Comment: Prussian blue stain highlights increased hepatocyte iron stores in some, but not all periportal regions. This relatively small amount does not exclude a diagnosis of hereditary hemochromatosis due to the variable penetrance of that disease. Genetic testing may be helpful. Secondary iron overload Cirrhosis (non-biliary) Alcoholic liver disease NAFLD HCV 11

Secondary iron overload Cirrhosis (non-biliary) Alcoholic liver disease NAFLD HCV: the virus itself? but also treatment related? Secondary iron overload Cirrhosis (non-biliary) Alcoholic liver disease NAFLD HCV: the virus itself? but also treatment related? Increased Hepatic Iron Deposition Resulting From Treatment of Chronic Hepatitis C With Ribavirin Fiel MI et al. Am J Clin Path 2000 Jan;113(1):35-9. HCV and iron Increased degree of inflammation Increased degree of fibrosis More fibrosis at younger age, especially if homozygous HCV and iron Increased degree of inflammation Increased degree of fibrosis More fibrosis at younger age, especially if homozygous >> Pre-Tx phlebotomy? 12

Other diseases HCV + HIV? Untreated HIV: Often more severe activity. Often more advanced disease. HCV + HIV? Untreated HIV: Often more severe activity. Often more advanced disease. Rare: fibrosing cholestatic hepatitis HCV + HIV? Untreated HIV: Often more severe activity. Often more advanced disease. Rare: fibrosing cholestatic hepatitis Beware: Infiltrating neoplasms, granulomas, HSV, CMV, biliary tract disease, etc. 13

HCV + HIV? On HAART: In large cohorts, possibly somewhat more aggressive, but individual biopsies look the same as HCV alone. Beware: drug toxicity Confirm clinical diagnosis Evaluate possible concomitant diseases Grade fibrosis Role of Liver Biopsy Stage necroinflammation Assess features of HCC risk Other diseases HCC risk screening Large cell change 14

Other diseases HCC risk screening Large cell change 1 st : Pre-malignant Other diseases HCC risk screening Large cell change 1 st : Pre-malignant Next: malignancy-associated, but NOT pre-malignant. Other diseases HCC risk screening Large cell change Now: Sometimes pre-malignant? Large liver cell change in hepatitis B virus-related liver cirrhosis. Kim H et al. Hepatology Sep 2009; 50: 752. Other diseases HCC risk screening Large cell change Small cell change 15

9/3/2009 Other diseases HCC risk screening Large cell change Small cell change Other diseases HCC risk screening Large cell change Small cell change Iron free foci Generally thought to be directly pre-malignant. 16

Case 3 52 year old woman with HCV and mild LFT elevation. Mass lesion noted on USG attempted biopsy of lesion. 17

Case 3: Diagnoses - Chronic hepatitis, mildly active with marked portal fibrosis (modified Ishak stage 1/4), compatible with hepatitis C. - Large cell change. - Small cell change. - Lipogranuloma. Case 4 61 year old Chinese woman with HBV (low serum HBV DNA) 18

19

Case 4: Diagnoses - Chronic hepatitis, mildly active with cirrhosis (modified Ishak stage 4/4) and possible features of regression, compatible with hepatitis B. - Hemosiderosis, grade 3/4 to 4/4,? Cirrhosis-associated vs. hereditary. - Large cell change. - Small cell change. - Iron free foci. Confirm clinical diagnosis Evaluate possible concomitant diseases Grade fibrosis Role of Liver Biopsy Stage necroinflammation Assess features of HCC risk 20

? 21